Evidence map›Paper›PMID 26334021›Full record

ArticleJournal of neurophysiology2015

Substance P excites GABAergic neurons in the mouse central amygdala through neurokinin 1 receptor activation.

L Sosulina, C Strippel, H Romo-Parra, A L Walter, T Kanyshkova, S B Sartori, M D Lange, N Singewald, H-C Pape

Open access · greenAbstract read
In one paragraph

Article in Journal of neurophysiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. A basal ganglia-like cortical-amygdalar-hypothalamic network mediates feeding behavior.Proceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

L SosulinaInstitute of Physiology I, Westfälische Wilhelms-Universität Münster, Münster, Germany; Neuronal Networks Group, Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Bonn, Germany.
C StrippelInstitute of Physiology I, Westfälische Wilhelms-Universität Münster, Münster, Germany;
H Romo-ParraInstitute of Physiology I, Westfälische Wilhelms-Universität Münster, Münster, Germany;
A L WalterInstitute of Physiology I, Westfälische Wilhelms-Universität Münster, Münster, Germany;
T KanyshkovaInstitute of Physiology I, Westfälische Wilhelms-Universität Münster, Münster, Germany;
S B SartoriDepartment of Pharmacology and Toxicology, Institute of Pharmacy, and Centre for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, Insbruck, Austria; and.
M D LangeInstitute of Physiology I, Westfälische Wilhelms-Universität Münster, Münster, Germany;
N SingewaldDepartment of Pharmacology and Toxicology, Institute of Pharmacy, and Centre for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, Insbruck, Austria; and.
H-C PapeInstitute of Physiology I, Westfälische Wilhelms-Universität Münster, Münster, Germany; papechris@ukmuenster.de.
University of Münster · DEUniversität Innsbruck · AT

Funding

Austrian Science Fund FWF P 25375
6 · The paper itself

Abstract

Substance P (SP) is implicated in stress regulation and affective and anxiety-related behavior. Particularly high expression has been found in the main output region of the amygdala complex, the central amygdala (CE). Here we investigated the cellular mechanisms of SP in CE in vitro, taking advantage of glutamic acid decarboxylase-green fluorescent protein (GAD67-GFP) knockin mice that yield a reliable labeling of GABAergic neurons, which comprise 95% of the neuronal population in the lateral section of CE (CEl). In GFP-positive neurons within CEl, SP caused a membrane depolarization and increase in input resistance, associated with an increase in action potential firing frequency. Under voltage-clamp conditions, the SP-specific membrane current reversed at -101.5 ± 2.8 mV and displayed inwardly rectifying properties indicative of a membrane K(+) conductance. Moreover, SP responses were blocked by the neurokinin type 1 receptor (NK1R) antagonist L-822429 and mimicked by the NK1R agonist [Sar(9),Met(O2)(11)]-SP. Immunofluorescence staining confirmed localization of NK1R in GFP-positive neurons in CEl, predominantly in PKCδ-negative neurons (80%) and in few PKCδ-positive neurons (17%). Differences in SP responses were not observed between the major types of CEl neurons (late firing, regular spiking, low-threshold bursting). In addition, SP increased the frequency and amplitude of GABAergic synaptic events in CEl neurons depending on upstream spike activity. These data indicate a NK1R-mediated increase in excitability and GABAergic activity in CEl neurons, which seems to mostly involve the PKCδ-negative subpopulation. This influence can be assumed to increase reciprocal interactions between CElon and CEloff pathways, thereby boosting the medial CE (CEm) output pathway and contributing to the anxiogenic-like action of SP in the amygdala.

Indexed as

AnimalsCentral Amygdaloid NucleusFluorescent Antibody TechniqueGABAergic NeuronsGene Knock-In TechniquesGlutamate DecarboxylaseGreen Fluorescent ProteinsMaleMembrane PotentialsMice, Inbred C57BLMice, TransgenicNeurokinin-1 Receptor AntagonistsPatch-Clamp TechniquesPiperidinesPotassiumProtein Kinase C-deltaGlutamate Decarboxylaseglutamate decarboxylase 1Green Fluorescent ProteinsN-((2-cyclopropoxy-5-(5-trifluomethyl)tetrazol-1-yl)benzyl)-2-phenylpiperidin-3-amineNeurokinin-1 Receptor AntagonistsPiperidinesPotassiumProtein Kinase C-deltaReceptors, Neurokinin-1Substance Pcentral amygdalaneurokinin type 1 receptorPKCδsubstance P

Identifiers

PMID26334021
PMCPMC4620133
OpenAlexW1774259331

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.